Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 6:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 816 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Butyrate Clear all
Terminated Phase 4 Interventional Results available

Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen

NCT01003249
View directory record Official record
Conditions
Overactive Bladder, Constipation, Lower Urinary Tract Symptoms
Interventions
Baclofen, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 64 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 25, 2026, 6:36 AM EDT
Not listed Phase 3 Interventional

Once Daily Gabapentin in the Treatment of Post Amputation Pain

NCT01776671
View directory record Official record
Conditions
Pain, Quality of Life
Interventions
Gralise
Drug
Lead sponsor
Chicago Anesthesia Pain Specialists
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Oct 25, 2026, 6:36 AM EDT
Recruiting Phase 1Phase 2 Interventional

Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

NCT04022239
View directory record Official record
Conditions
Hematopoietic and Lymphoid System Neoplasm
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Bendamustine, Cyclophosphamide, Filgrastim-sndz, Fludarabine, Melphalan, Mycophenolate Mofetil, Rituximab, Tacrolimus, Total-Body Irradiation
Procedure · Drug · Biological + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 25, 2026, 6:36 AM EDT
Recruiting Phase 2 Interventional

The Use of Butyrate Therapy in Pediatric Ulcerative Colitis

NCT05218850
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Butyrate
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
7 Years to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 25, 2026, 6:36 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors

NCT01265550
View directory record Official record
Conditions
GERD
Interventions
Nissen fundoplication, baclofen, Desipramine
Device · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 64 Years
Enrollment
366 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
15
States / cities
Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 25, 2026, 6:36 AM EDT
Completed Phase 2Phase 3 Interventional

Gabapentin in Fibromyalgia Trial (GIFT)

NCT00057278
View directory record Official record
Conditions
Fibromyalgia
Interventions
gabapentin
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
3
States / cities
Belmont, Massachusetts • Newton, Massachusetts • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 19, 2007 · Synced Oct 25, 2026, 6:36 AM EDT
Terminated Phase 3 Interventional Results available

Pregabalin Versus Placebo In The Treatment Of Neuropathic Pain Associated With HIV Neuropathy

NCT01049217
View directory record Official record
Conditions
Neuropathy
Interventions
pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • North Hollywood, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 25, 2026, 6:36 AM EDT
Completed Phase 1 Interventional Results available

Effect of Prebiotics on the Gut Microbiome Profile and Beta Cell Function

NCT04114357
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Acetylated and Butyrylated High Amylose Maize Starch
Drug
Lead sponsor
Indiana University
Other
Eligibility
11 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 25, 2026, 6:36 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate Daily Pravastatin, Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia

NCT00459745
View directory record Official record
Conditions
Combined Hyperlipidemia
Interventions
Pravafen, Pravastatin, Fenofibrate
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 75 Years
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
57
States / cities
Phoenix, Arizona • Sierra Vista, Arizona • Long Beach, California + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 25, 2026, 6:36 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)

NCT01474772
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Pregabalin, placebo
Drug · Other
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
34
States / cities
Goodyear, Arizona • Phoenix, Arizona • Fresno, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 25, 2026, 6:36 AM EDT
Completed Phase 1 Interventional

Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer

NCT02240719
View directory record Official record
Conditions
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia, Multiple Myeloma
Interventions
everolimus, bendamustine hydrochloride
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 25, 2026, 6:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Fenofibrate 160mg Tablets Under Fed Conditions

NCT00775359
View directory record Official record
Conditions
Healthy
Interventions
Fenofibrate 160 mg tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 20, 2008 · Synced Oct 25, 2026, 6:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Evacetrapib in Healthy Participants

NCT01736254
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Evacetrapib, Gemfibrozil
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 25, 2026, 6:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3A

NCT03624959
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Ozanimod, Gemfibrozil, Itraconazole, Rifampin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Oct 25, 2026, 6:36 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluating the Effects of Propionate and Butyrate Supplementation on the Intestinal Health of Healthy Volunteers

NCT07611370
View directory record Official record
Conditions
Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Microencapsulated Sodium Butyrate, Microencapsulated Sodium Propionate
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 25, 2026, 6:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effects of Pregabalin on Pain After Total Knee Arthroplasty

NCT01333956
View directory record Official record
Conditions
Primary Total Knee Arthroplasty
Interventions
Pregabalin 50mg, Pregabalin 100mg, Pregabalin 150mg, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 25, 2026, 6:36 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence

NCT00730522
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
CPP-109 vigabatrin, Matching Placebo
Drug
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Oceanside, California • San Diego, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 25, 2026, 6:36 AM EDT
Completed Phase 2 Interventional Results available

Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia

NCT00504829
View directory record Official record
Conditions
Dyslipidemia
Interventions
LCP-AtorFen, atorvastatin, fenofibrate
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 25, 2026, 6:36 AM EDT
Completed Phase 2 Interventional

Diabetic Peripheral Neuropathic Pain (DPNP)

NCT01314222
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
BMS-954561, Pregabalin, Placebo matching BMS-954561, Placebo matching Pregabalin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 85 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • Lomita, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 25, 2026, 6:36 AM EDT
Completed Phase 2 Interventional Results available

Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis

NCT01222260
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Bendamustine, Dexamethasone
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
6
States / cities
Boston, Massachusetts • Detroit, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 25, 2026, 6:36 AM EDT
Withdrawn Phase 1 Interventional

Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma

NCT02315157
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Leukemia
Interventions
Bendamustine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 25, 2026, 6:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Next-Generation Synbiotic in Individuals With Overweight or Obesity

NCT06213480
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Synbiotic Group, Placebo Group
Dietary Supplement · Other
Lead sponsor
Texas Christian University
Other
Eligibility
18 Years to 50 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 25, 2026, 6:36 AM EDT
Completed Phase 3 Interventional Results available

Effectiveness of Gabapentin When Used With Naltrexone to Treat Alcohol Dependence Compared to Placebo and Naltrexone Alone

NCT00183196
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Naltrexone, Naltrexone plus Gabapentin, Inactive Placebo
Drug · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Oct 25, 2026, 6:36 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)

NCT00947388
View directory record Official record
Conditions
Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma
Interventions
Bendamustine Hydrochloride, Alemtuzumab
Drug · Biological
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Oct 25, 2026, 6:36 AM EDT